• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在缺乏衰变加速因子保护的情况下,对实验性自身免疫性重症肌无力的易感性显著增强。

Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.

作者信息

Lin Feng, Kaminski Henry J, Conti-Fine Bianca M, Wang Wei, Richmonds Chelliah, Medof M Edward

机构信息

Institute of Pathology, Case Western Reserve University, University Hospitals of Cleveland, and Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio 44106, USA.

出版信息

J Clin Invest. 2002 Nov;110(9):1269-74. doi: 10.1172/JCI16086.

DOI:10.1172/JCI16086
PMID:12417565
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC151616/
Abstract

Myasthenia gravis (MG) is an autoimmune neuromuscular transmission disorder characterized by loss of acetylcholine receptors (AChR's) due primarily to the production of anti-AChR autoantibodies. In this study we investigated whether the presence of decay-accelerating factor (DAF or CD55), an intrinsic complement regulator, protects against the development of disease. Experimental autoimmune MG was induced in Daf1(-/-) mice (devoid of neuromuscular DAF protein) and their Daf1(+/+) littermates by injection of rat anti-AChR mAb McAb-3. After twenty-four hours, grip strength assessment revealed that Daf1(-/-) mice exhibited hold times of less than 30 seconds, compared with more than 8 minutes for the Daf1(+/+) controls. The weakness was reversed by edrophonium, consistent with a myasthenic disorder. Immunohistochemistry revealed greatly augmented C3b deposition localized at postsynaptic junctions, and radioimmunoassays showed more profound reductions in AChR levels. Electron microscopy demonstrated markedly greater junctional damage in the Daf1(-/-) mice compared with the Daf1(+/+) littermates. Control studies showed equivalent levels of other cell surface regulators, i.e., Crry and CD59. The results demonstrate that mice that lack DAF are markedly more susceptible to anti-AChR-induced MG, which simulates the primary mechanism in the human disease, and strongly suggest that in disease flares complement inhibitors might have therapeutic value.

摘要

重症肌无力(MG)是一种自身免疫性神经肌肉传递障碍疾病,主要特征是由于抗乙酰胆碱受体(AChR)自身抗体的产生导致乙酰胆碱受体丧失。在本研究中,我们调查了内源性补体调节因子衰变加速因子(DAF或CD55)的存在是否能预防疾病的发生。通过注射大鼠抗AChR单克隆抗体McAb-3,在Daf1(-/-)小鼠(缺乏神经肌肉DAF蛋白)及其Daf1(+/+)同窝小鼠中诱导实验性自身免疫性MG。24小时后,握力评估显示,Daf1(-/-)小鼠的抓握时间少于30秒,而Daf1(+/+)对照小鼠的抓握时间超过8分钟。依酚氯铵可逆转肌无力症状,这与重症肌无力疾病相符。免疫组织化学显示,突触后连接处的C3b沉积显著增加,放射免疫分析显示AChR水平下降更为明显。电子显微镜显示,与Daf1(+/+)同窝小鼠相比,Daf1(-/-)小鼠的突触损伤明显更严重。对照研究表明,其他细胞表面调节因子,即Crry和CD59的水平相当。结果表明,缺乏DAF的小鼠对抗AChR诱导的MG明显更易感,这模拟了人类疾病的主要机制,并强烈提示在疾病发作时补体抑制剂可能具有治疗价值。

相似文献

1
Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.在缺乏衰变加速因子保护的情况下,对实验性自身免疫性重症肌无力的易感性显著增强。
J Clin Invest. 2002 Nov;110(9):1269-74. doi: 10.1172/JCI16086.
2
Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia.衰变加速因子和CD59的缺乏会导致实验性重症肌无力危象。
Exp Neurol. 2006 Dec;202(2):287-93. doi: 10.1016/j.expneurol.2006.06.003. Epub 2006 Jul 20.
3
Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.眼外肌与实验性自身免疫性重症肌无力中的补体调节蛋白
Exp Neurol. 2004 Oct;189(2):333-42. doi: 10.1016/j.expneurol.2004.06.005.
4
Cell surface complement regulators moderate experimental myasthenia gravis pathology.细胞表面补体调控因子调节实验性重症肌无力病理。
Muscle Nerve. 2013 Jan;47(1):33-40. doi: 10.1002/mus.23448. Epub 2012 Oct 5.
5
The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice.补体的膜攻击途径在被动诱导的小鼠实验性自身免疫性重症肌无力中引发病理变化。
Clin Exp Immunol. 2006 Nov;146(2):294-302. doi: 10.1111/j.1365-2249.2006.03205.x.
6
Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.补体调节蛋白CD59缺乏不会增加主动诱导的实验性自身免疫性重症肌无力的易感性。
J Neuroimmunol. 2006 Dec;181(1-2):29-33. doi: 10.1016/j.jneuroim.2006.07.016. Epub 2006 Oct 23.
7
Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis.衰变加速因子和CD59在急性肾毒性血清性肾炎中规避肾小球损伤的各自作用。
J Immunol. 2004 Feb 15;172(4):2636-42. doi: 10.4049/jimmunol.172.4.2636.
8
Ocular myasthenia gravis induced by human acetylcholine receptor ϵ subunit immunization in HLA DR3 transgenic mice.在HLA DR3转基因小鼠中,由人乙酰胆碱受体ε亚基免疫诱导的眼肌型重症肌无力
Immunol Lett. 2015 Dec;168(2):306-12. doi: 10.1016/j.imlet.2015.10.009. Epub 2015 Oct 19.
9
DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis.补体调节蛋白 DAF/CD55 和 Protectin/CD59 调节实验性自身免疫性重症肌无力中的适应性免疫和疾病结局。
J Neuroimmunol. 2012 Mar;244(1-2):63-9. doi: 10.1016/j.jneuroim.2012.01.003. Epub 2012 Feb 10.
10
A new mouse model of autoimmune ocular myasthenia gravis.一种自身免疫性眼肌型重症肌无力的新型小鼠模型。
Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5101-11. doi: 10.1167/iovs.07-0271.

引用本文的文献

1
Therapeutic strategies targeting complement in myasthenia gravis patients.针对重症肌无力患者补体的治疗策略。
J Neurol. 2025 Jul 2;272(8):489. doi: 10.1007/s00415-025-13225-7.
2
Treating myasthenia gravis beyond the eye clinic.眼肌型重症肌无力的治疗不应局限于眼科。
Eye (Lond). 2024 Aug;38(12):2422-2436. doi: 10.1038/s41433-024-03133-x. Epub 2024 May 24.
3
Emerging role of complement in COVID-19 and other respiratory virus diseases.补体系统在 COVID-19 和其他呼吸道病毒疾病中的新作用。
Cell Mol Life Sci. 2024 Feb 18;81(1):94. doi: 10.1007/s00018-024-05157-8.
4
Role of complement in myasthenia gravis.补体在重症肌无力中的作用。
Front Neurol. 2023 Oct 5;14:1277596. doi: 10.3389/fneur.2023.1277596. eCollection 2023.
5
Heterogeneity of Acetylcholine Receptor Autoantibody-Mediated Complement Activity in Patients With Myasthenia Gravis.乙酰胆碱受体自身抗体介导的补体活性在重症肌无力患者中的异质性。
Neurol Neuroimmunol Neuroinflamm. 2022 Apr 26;9(4). doi: 10.1212/NXI.0000000000001169. Print 2022 Jul.
6
The emerging role of complement in neuromuscular disorders.补体系统在神经肌肉疾病中的新作用。
Semin Immunopathol. 2021 Dec;43(6):817-828. doi: 10.1007/s00281-021-00895-4. Epub 2021 Oct 27.
7
Complement Inhibition for the Treatment of Myasthenia Gravis.补体抑制治疗重症肌无力
Immunotargets Ther. 2020 Dec 15;9:317-331. doi: 10.2147/ITT.S261414. eCollection 2020.
8
Complement Inhibitor Therapy for Myasthenia Gravis.补体抑制剂治疗重症肌无力。
Front Immunol. 2020 Jun 3;11:917. doi: 10.3389/fimmu.2020.00917. eCollection 2020.
9
Complementopathies and precision medicine.补体系统相关疾病与精准医学
J Clin Invest. 2020 May 1;130(5):2152-2163. doi: 10.1172/JCI136094.
10
Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.补体在重症肌无力和视神经脊髓炎谱系疾病中的作用及补体抑制剂的潜力:简要综述。
J Neurol. 2021 May;268(5):1643-1664. doi: 10.1007/s00415-019-09498-4. Epub 2019 Sep 3.

本文引用的文献

1
Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis.衰变加速因子可保护急性肾毒性肾炎中的足细胞免受补体介导的损伤。
Lab Invest. 2002 May;82(5):563-9. doi: 10.1038/labinvest.3780451.
2
Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies.小鼠衰变加速因子(DAF)基因产物的组织分布。利用Daf1基因敲除小鼠和位点特异性单克隆抗体。
Immunology. 2001 Oct;104(2):215-25. doi: 10.1046/j.1365-2567.2001.01287.x.
3
Extraocular muscle is defined by a fundamentally distinct gene expression profile.眼外肌由一种根本不同的基因表达谱所定义。
Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12062-7. doi: 10.1073/pnas.211257298. Epub 2001 Sep 25.
4
Safety factor at the neuromuscular junction.神经肌肉接头处的安全系数。
Prog Neurobiol. 2001 Jul;64(4):393-429. doi: 10.1016/s0301-0082(00)00055-1.
5
Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice.干扰素-γ或白细胞介素-12的缺失对C57BL/6小鼠实验性重症肌无力有不同影响。
J Immunol. 2000 May 15;164(10):5236-44. doi: 10.4049/jimmunol.164.10.5236.
6
Acetylcholine receptors and myasthenia.乙酰胆碱受体与重症肌无力
Muscle Nerve. 2000 Apr;23(4):453-77. doi: 10.1002/(sici)1097-4598(200004)23:4<453::aid-mus3>3.0.co;2-o.
7
A critical role for murine complement regulator crry in fetomaternal tolerance.小鼠补体调节因子Crry在母胎耐受中起关键作用。
Science. 2000 Jan 21;287(5452):498-501. doi: 10.1126/science.287.5452.498.
8
Disorders of neuromuscular junction ion channels.神经肌肉接头离子通道疾病。
Am J Med. 1999 Jan;106(1):97-113. doi: 10.1016/s0002-9343(98)00374-x.
9
Interleukin-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor.白细胞介素-4缺乏促进实验性重症肌无力的发展,并阻止通过鼻腔给予乙酰胆碱受体的CD4 +表位序列来预防该疾病。
J Neuroimmunol. 1999 Mar 1;95(1-2):73-84. doi: 10.1016/s0165-5728(98)00262-8.
10
Antibody effector mechanisms in myasthenia gravis. The complement hypothesis.重症肌无力中的抗体效应机制。补体假说。
Ann N Y Acad Sci. 1998 May 13;841:450-65. doi: 10.1111/j.1749-6632.1998.tb10962.x.